Oregon Cannabis Tax Act 2012 Media Coverage – KATU2


Oregon Cannabis Tax Act 2012 Media Coverage – KATU2 – The Oregon Cannabis Tax Act has been approved for circulation. The certified ballot title is as follows: Allows personal marijuana, hemp cultivation/use without license; commission to regulate commercial marijuana cultivation/sale. Result of a “Yes” Vote: “Yes” vote allows commercial marijuana (cannabis) cultivation/sale to adults through state-licensed stores; allows unlicensed adult personal cultivation/use; prohibits restrictions on hemp (defined). Result of a “No” Vote: “No” vote retains existing civil and criminal laws prohibiting cultivation, possession and delivery of marijuana; retains current statutes that permit regulated medical use of marijuana. Summary: Currently, marijuana cultivation, possession and delivery are prohibited; regulated medical marijuana use is permitted. Measure replaces state, local marijuana laws except medical marijuana and driving under the influence laws; distinguishes “hemp” from “marijuana”; prohibits regulation of hemp. Creates commission to license marijuana cultivation by qualified persons and to purchase entire crop. Commission sells marijuana at cost to pharmacies, medical research facilities, and to qualified adults for profit through state-licensed stores. Ninety percent of net goes to state general fund, remainder to drug education, treatment, hemp promotion. Bans sales to, possession by minors. Bans public consumption except where signs permit, minors barred. Commission regulates use, sets prices, other duties; Attorney


2013 NFL Draft: Overrated Prospects Not Worthy of First-Round Pick

Filed under: drug treatment news 2013

In an early look at some of the top prospects in the 2013 NFL draft, here are the overrated prospects who have no business being in the first-round conversation. USC QB Matt Barkley … Then he was suspended to start the 2012 season for a failed drug test.
Read more on Bleacher Report


RedHill Biopharma dual-lists on Nasdaq

Filed under: drug treatment news 2013

RedHill is entering the US financial market with six drugs in late clinical-stages of development and a strong balance sheet." RedHill will begin a Phase III clinical trial of RHB-104 for the treatment of Crohn's disease in the first half of 2013, a …
Read more on Globes